Impact of CT-apelin and NT-proBNP on identifying non-responders to cardiac resynchronization therapy.
Assessment of response to cardiac resynchronization therapy (CRT) is essential. To assess the predictive value of CT-apelin together with NT-proBNP in patients undergoing CRT. Serum CT-apelin and NT-proBNP were measured by ELISA before, and six months after CRT. Primary endpoint was non-response (<4% increase in LVEF) after six months. From 81 patients, 15 proved to be non-responders. Six-month CT-apelin was superior compared to NT-proBNP in identifying non-responders by multivariate ROC (CT-apelin: p = 0.01, NT-proBNP: p = 0.13) and by logistic regression (CT-apelin: p = 0.01, NT-proBNP: p = 0.41) analyses. Six-month CT-apelin might be a valuable novel biomarker in identifying non-responders to CRT that was superior to NT-proBNP.